Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedNo significant changes detected in core content; only cosmetic formatting changes were observed on the Study Details page, and there are no updates to inclusion criteria, primary outcomes, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check15 days agoNo Change Detected
- Check36 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference2%

- Check43 days agoChange DetectedTerminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and page version bumped from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page revision was updated from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.SummaryDifference0.1%

- Check65 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check72 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as new medical terms related to plasma cell myeloma and various compounds. Notably, several previous terms related to multiple myeloma treatments have been removed.SummaryDifference2%

Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.